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Abstract
Genomic surveillance is an important aspect of contemporary disease
management but has yet to be used routinely to monitor endemic disease
transmission and control in low- and middle-income countries. Rabies is an
almost invariably fatal viral disease that causes a large public health and
economic burden in Asia and Africa, despite being entirely vaccine
preventable. With policy efforts now directed towards achieving a global
goal of zero dog-mediated human rabies deaths by 2030, establishing
effective surveillance tools is critical. Genomic data can provide important
and unique insights into rabies spread and persistence that can direct
control efforts. However, capacity for genomic research in low- and
middle-income countries is held back by limited laboratory infrastructure,
cost, supply chains and other logistical challenges. Here we present and
validate an end-to-end workflow to facilitate affordable whole genome
sequencing for rabies surveillance utilising nanopore technology. We used
this workflow in Kenya, Tanzania and the Philippines to generate rabies
virus genomes in two to three days, reducing costs to approximately £60
per genome. This is over half the cost of metagenomic sequencing
previously conducted for Tanzanian samples, which involved exporting
samples to the UK and a three- to six-month lag time. Ongoing optimization
of workflows are likely to reduce these costs further. We also present tools
to support routine whole genome sequencing and interpretation for
genomic surveillance. Moreover, combined with training workshops to
empower scientists in-country, we show that local sequencing capacity can
be readily established and sustainable, negating the common
misperception that cutting-edge genomic research can only be conducted
in high resource laboratories. More generally, we argue that the capacity to
harness genomic data is a game-changer for endemic disease surveillance
and should precipitate a new wave of researchers from low- and
middle-income countries.
Keywords
dog-mediated rabies, field sequencing, lyssavirus, MinION, nanopore,
neglected tropical diseases, phylogenetic, rabies virus, whole genome
sequencing, zoonoses, surveillance
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Abbreviations
RABV, rabies virus; LMICs, low- and middle-income countries; 
ONT, Oxford Nanopore Technology; APHA, Animal and Plant 
Health Agency; RITM, Research Institute for Tropical Medi-
cine; UNITID, University of Nairobi Institute of Tropical and 
Infectious Diseases; WGS, whole genome sequencing; RIDT, 
rapid immunodiagnostic test.
Introduction
Surveillance is critical to inform infectious disease manage-
ment and control programmes (Klepac et al., 2013; Molyneux 
et al., 2004) and genomic data is emerging as a powerful new 
surveillance tool (Cotton et al., 2018). Pathogen sequencing has 
become increasingly routine in well-resourced public health 
laboratories, but in low- and middle-income countries 
(LMICs) where most emerging and endemic zoonoses occur, 
sequencing capacity is more limited and the direct applica-
tion of genomics-informed surveillance is still at an early stage 
(Balloux et al., 2018; Folarin et al., 2014; Gardy & Loman, 2018).
Oxford Nanopore Technologies’ (ONT) MinION machine has 
revolutionized genomic sequencing capacity (Johnson et al., 
2017). This portable, low-cost sequencer has supported innova-
tive “lab-in-a-suitcase” platforms to diagnose crop pathogens 
in situ (Boykin et al., 2018; Boykin et al., 2019) and enable 
real-time outbreak surveillance of emerging pathogens, such as 
Ebola, Yellow Fever and Zika viruses (Faria et al., 2018; Faria 
et al., 2016; Quick et al., 2015; Quick et al., 2016; Quick et al., 
2017). There is potential to extend genomic technologies to 
endemic pathogens such as rabies, foot-and-mouth disease, 
brucellosis and bovine tuberculosis, which are responsible for 
major impacts on people’s health and livelihoods on a daily 
basis (Cleaveland et al., 2017; Danielsen et al., 2019; Halliday 
et al., 2015). Such an approach could reduce the lag time from 
sample to sequence and epidemiological action that is typical 
for these neglected diseases, while simultaneously building 
genomic capacity in LMICs. Investing in the surveillance 
of these endemic pathogens builds core capacities necessary for 
the detection of unusual disease emergence events that precede 
epidemics (Cleaveland et al., 2017; Halliday et al., 2017).
Genomic surveillance has potential applications for manage-
ment of a range of endemic zoonoses. Here we focus on the 
development and deployment of genomic surveillance tools 
to support rabies control and elimination programmes. Rabies 
is a devastating, invariably fatal zoonotic disease caused 
by a single stranded negative-sense RNA virus (Brunker & 
Mollentze, 2018). Rabies is globally widespread and can infect 
and be transmitted by all mammal species, but the vast majority 
of human deaths worldwide result from bites by infected domes-
tic dogs (WHO, 2018a). Canine rabies elimination is feasible 
through sustained well-implemented mass dog vaccination 
programmes (Abela-Ridder et al., 2016; Lankester et al., 2014; 
WHO, 2018b). A global initiative to end human deaths from 
dog-mediated rabies by 2030 is now underway (WHO, 2018b) 
and practical, effective surveillance tools are required to sup-
port this campaign (Benavides et al., 2019; Bitek et al., 2019; 
Broban et al., 2018; Hampson et al., 2016; Mtema et al., 2016).
Genomic surveillance can inform global efforts to eliminate 
dog-mediated rabies and may be particularly valuable during the 
endgame, when the disease can circulate for extended periods 
at low levels (Klepac et al., 2013). Endemic rabies typically cir-
culates at low levels in dog populations (e.g. 58 to 384 cases 
per 100,000 dogs in low to high incidence settings in 
Tanzania, Hampson et al., 2016) and during endgame stages 
incidence can drop below detectable levels with traditional sur-
veillance, often based on laboratory-based confirmation of 
submitted suspect cases. Enhanced surveillance including inte-
grated bite case management can increase case detection up to 
ten-fold (Suseno et al., 2019) and genetic data from cases 
detected during this period is critical in determining their role in 
maintaining circulation and dispersing infection. For example: 
differentiating dog rabies variants from other wildlife variants 
(Lembo et al., 2007); distinguishing ongoing endemic trans-
mission from incursions (Bourhy et al., 2016; Mollentze et al., 
2014b; Zinsstag et al., 2017); and identifying sources of 
incursions (Mollentze et al., 2013; Tohma et al., 2016). 
Furthermore, the capacity for an informed rapid response to 
newly detected cases will be pivotal for control efforts to succeed 
(Henderson, 2011).
Here we establish methods for rapid whole genome sequenc-
ing (WGS) of rabies viruses (RABV) using the MinION 
sequencer, including a workflow from sample to sequence and 
the associated bioinformatics pipeline. We also incorporate pro-
cedures for downstream analysis, interpretation, and manage-
ment of genomic data in a surveillance context. Through testing 
and replication of methods across different locations in Kenya, 
Tanzania and the Philippines we demonstrate the feasibility 
of real-time sequencing of RABV to rapidly inform policy 
decisions and disease management. We further highlight the 
potential for cost savings that could make routine genomic 
surveillance of rabies affordable in low-resource endemic 
settings.
Methods
Rabies positive samples were processed under a range of condi-
tions to generate near whole genome sequences for viral char-
acterization and phylogenetic analysis. Here we describe the 
sequencing and bioinformatics pipelines and validation process, 
detailing adaptations required for different settings. Our aim was 
to establish a protocol that could be used under minimal laboratory 
infrastructure; therefore, the approach is supported by a lab-in-a-
suitcase platform: a portable toolkit to support the steps required 
to get from sample to sequence (Figure 1). A comprehensive, 
            Amendments from Version 1
Version 2 of the manuscripts has been revised based on three 
reviewer’s comments. We also provide more detailed phylogenetic 
trees in Figure 6 and Figure 7.
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end of the article
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up-to-date sample-to-sequence laboratory protocol is available 
on protocols.io and supporting pipelines can be found on GitHub 
will be updated with improvements as methods develop. The 
ARTIC network, a Wellcome funded project to develop the 
application of genomic surveillance for viral outbreak response, 
provides comprehensive open-source resources for laboratory 
and sequencing work, bioinformatics, phylogenetics and analy-
sis. We take advantage of these resources for our rabies work-
flow. They can be found here on the ARTIC network website 
and are published in Quick et al., 2017. We also utilise RABV-
GLUE (Singer et al., 2018), a general-purpose resource for 
analysis, interpretation, and management of RABV genome 
data, to organise and interpret RABV consensus sequences.
Samples
Brain tissue samples were collected by field officers and 
veterinarians from suspect rabid animals as part of rabies sur-
veillance and research projects across Kenya (n = 9), Tanzania 
(n = 26, with 2 archived samples processed in the UK) and the 
Philippines (n = 52). These samples were accessible through 
existing collaborations and time allowed for their processing 
whilst optimizing our protocols and delivering training work-
shops, therefore numbers do not necessarily represent the sur-
veillance capacity in each locality. Samples were obtained 
predominantly from domestic dogs but also included livestock 
and wildlife samples; details are provided as underlying data 
(Brunker, 2019b). Samples were processed in settings with 
varying infrastructure and resources, from central diagnostic 
laboratories to field sites. Details of each site can be found in 
Table 1 and Figure 2. Rapid immunodiagnostic tests (RIDT), 
manufactured by BioNote, Inc. (RG18.01, Gyeongi-do, Repub-
lic of Korea), were used to confirm rabies positive cases in the 
field in Tanzania. These kits have been validated as an effec-
tive rabies field diagnostic tool (Léchenne et al., 2016). In 
Kenya, samples were confirmed positive by the Kenya Medical 
Research Institute (KEMRI) using the direct rapid immunohis-
tochemical test (dRIT) and tested by RIDT prior to sequencing. 
In the Philippines samples were tested by the Research Insti-
tute for Tropical Medicine (RITM) using the fluorescent 
antibody test (FAT) (Abela-Ridder, 2018).
Equipment
A full suite of portable, battery-powered equipment and labo-
ratory consumables was put together based on the ARTIC 
network’s published kit list. Reagents that required cold chain 
transportation were carried in polystyrene temperature control 
boxes packed with ice packs frozen at -20 or -80°C prior to use. 
This equipment, including reagent boxes, could be packed into 
standard airline sized checked luggage (lab-in-a-suitcase) for 
transportation (Figure 1).
Sample preparation and RNA extraction
Methods to perform sample processing and RNA extraction 
varied according to resources available on site. In research 
or diagnostic laboratories, samples were handled in contain-
ment level (CL) 2+ or CL3 conditions until sample inactiva-
tion. At field sites, samples were handled in a portable glove box 
(UY-33666-50, Cole Parmer). RNA extraction was performed 
using the Zymo Quick RNA Miniprep kit (R1054, Zymo 
Research) according to the manufacturer’s protocol. Sample prep-
aration varied according to the state of the sample (fresh/frozen, 
homogenised/non-homogenised) and its preservation (RNAlater 
[Invitrogen], DNA/RNA Shield [Zymo Research], 50% glycerol-
saline solution). Recommended methods for different sample 
types can be found in the manufacturer’s instructions but gener-
ally the following protocol was used. A small amount of brain 
tissue (50–100mg) was transferred from the original sample 
tube, using a wooden applicator stick or toothpick, to a 2ml 
reinforced homogeniser tube containing 1.4mm ceramic 
beads (Qiagen) and ~1ml of Zymo kit RNA lysis buffer. The 
Figure  1. Rabies “lab-in-a-suitcase”  setup  for  sequencing  in  low-resource  settings. A) Lab-in-a-suitcase being used at the Nelson 
Mandela African Institute of Science and Technology, Tanzania; B) RNA extractions performed in the back of a vehicle using a portable glove 
box and battery-powered centrifuge in Makueni District, Kenya; C) Laboratory setup for sample inactivations in a district livestock office in 
Mugumu, Serengeti District, Tanzania. 
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Figure 2. Locations  in East Africa where sequencing of rabies viruses was performed. Circles are scaled according to numbers of 
samples sequenced. Details of laboratory capacity at each site are provided as underlying data (Brunker, 2019b).
sample was homogenised using a Terralyzer (Zymo Research) with 
30 second pulses until fully homogenised and left to inactivate 
for 2 minutes. When a Terralyzer was unavailable, samples 
were manually homogenised using a toothpick. Lysed samples 
were processed according to manufacturer’s column-based 
RNA purification protocol with in-column DNase I treatment 
to remove genomic DNA. In brief, lysed samples were added to 
filter columns and subject to a series of centrifugation steps to 
selectively bind RNA and purify (ethanol washes) and finally 
eluted. Purified viral RNA was eluted in 50µl DNase/RNase-Free 
Water. Aliquots of four samples stored in RNA later were 
shipped on dry ice from Tanzania to the Animal & Plant Health 
Agency (APHA, Weybridge UK) in 2017. These, and two sam-
ples used for validation (see below), were extracted accord-
ing to a previously described Trizol-based method at APHA 
(Brunker et al., 2015). Briefly, 50–100mg of brain tissue was 
homogenised in 1ml Trizol and 200µl chloroform added to ena-
ble phase separation. RNA separates into the upper aqueous 
phase, which is removed and RNA precipitated using isopropa-
nol. This is followed by centrifugation to pellet RNA and ethanol 
washes to purify, with elution in DNase/RNase-Free Water.
Multiplex primer design and validation
Multiplex primer schemes were designed for RABV using 
Primal Scheme. For Tanzania, a set of 10 reference sequences 
from datasets curated and filtered in RABV-GLUE were chosen 
to represent the known RABV diversity in Tanzania (in file 
order submitted to Primal Scheme: KR906748.1, KR906747.1, 
KY210263.1, KY210264.1, KY210227.1, KR906774.1, 
KR906763.1, KR906742.1, KR534218.2, KY210305.1). Settings 
were applied to generate primers for 400bp amplicons across 
the entire genome (~11923bp), with an overlap of 50bp. A 
short amplicon length was chosen due to previous experience 
of poor sample quality from field collected and stored samples 
resulting in RNA fragmentation and a low viral copy number 
(Brunker et al., 2015; Brunker et al., 2018). The first scheme 
created, rabvTanzDg, was tested on archived Tanzanian RABV 
RNA samples at APHA following the protocol described in 
Quick et al. (2016). Two sequencing validations were performed: 
1) Amplicons from one sample, RV3227, were sequenced on 
an Illumina NextSeq to confirm the amplification of individ-
ual products across the genome. This sample had already been 
sequenced using a PCR-free metagenomic approach, briefly 
described in section “Additional Sequencing” (described in 
Brunker et al., 2015), providing a comparison between library 
preparations; 2) Subsequently, amplicons from another 
sample (RAB16025) were sequenced on both the MinION and 
NextSeq (fragmented before sequencing on NextSeq). In addi-
tion, metagenomic sequencing was conducted on the NextSeq 
for this sample. A second RABV scheme was produced for the 
Philippines (rabvSEasia) following the same approach and 
used directly for MinION sequencing (reference sequences: 
KX148260, KX148263, N-gene 99% consensus sequence of 
[AB116581, AB116582, AB683592:AB683635], AB981664, 
KX148255, JN786878, KX148250, KX148254, EU293111, 
KX148248, KX148266).
DNA preparation
Protocols and reagents varied slightly due to availability 
and as protocols evolved; the latest version of the protocol 
is available on the GitHub resource and Figshare (Brunker, 
2019d). Initially, extracted RNA was reverse transcribed using 
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Protoscript II First Strand Sequencing kit (E6560, NEB) under 
manufacturer’s instructions. At later stages this was changed to 
Lunascript RT Supermix (E3010, NEB) in a reduced reaction 
volume of 10µl (2µl Lunascript + 3µl nuclease-free water +5µl 
RNA). Multiplex PCR was conducted with 2 to 2.5 µL of 
cDNA, the RABV primer scheme and Q5 High Fidelity Hot-
Start DNA Polymerase (M0493, NEB) following the two-step 
PCR protocol (Quick et al., 2017), with the following PCR 
cycling conditions: 98°C heat inactivation for 30sec, followed 
by 30–40 cycles of denaturation at 98°C for 15sec and a 
combined extension/annealing step of 65°C for 5min. PCR prod-
ucts were purified using a 1x solid-phase reversible immobi-
lization bead (SPRI) cleanup (Ampure XP, Beckman-Coulter 
or PCRClean DX,Aline Biosciences) and concentrations meas-
ured using a Qubit dsDNA High Sensitivity kit (Q32851, 
Thermofisher) on a Qubit 3.0 fluorimeter (ThermoFisher). In 
field sites, or when standard thermocyclers in laboratories were 
unavailable, PCR was performed using a portable MiniPCR 
machine (Amplyus). This was powered by a lithium battery 
(PowerAdd Pilot Pro2 85Wh LiION 9-20V) for the full PCR 
cycle when power was intermittent or unavailable. A negative 
control (water) was included at the cDNA synthesis stage for 
each batch of samples and as part of the sequencing library. Some 
of the first runs in Tanzania did not include a negative control 
as part of the sequencing library as the protocol was still being 
finalised. However, a negative control up to the PCR stage 
was always included as part of sample preparation. If the 
negative control was >1ng/µl by Qubit quantification, sample 
preparation was repeated from RNA extraction.
MinION library preparation and sequencing
Library preparation for the MinION was conducted using Ligation 
Sequencing 1D (SQK-LSK108/SQK-LSK109, ONT) and Native 
Barcoding kits (EXP-NBD103/EXP-NBD104/EXP-NBD114, 
ONT) on FLO-MIN106 (R9.4/R9.4.1, ONT) flowcells 
according to the manufacturer’s instructions and modifications 
as per Quick et al. (2017). Briefly, DNA prepared in the previ-
ous step (PCR amplicon pools for each sample were pooled) 
was end-repaired and dA-tailed using an UltraII End Prep Reac-
tion Module (E7442, NEB) followed by ligation of barcodes 
using the NEBNext UltraII Ligation module (E7595, NEB) 
in a “one-pot” reaction. Following barcode ligation, samples were 
purified using a SPRI bead cleanup and pooled together into a sin-
gle tube before ONT adaptor ligation with the NEBNext UltraII 
Ligation module. Ligated DNA was then cleaned using a SPRI 
bead clean-up with ABB/SFB (SQK-LSK108/SQK-LSK109, 
ONT) washes and final library elution in ONT’s elution buffer 
(SQK-LSK108/SQK-LSK109, ONT). With the latest kit ver-
sions, up to 24 native barcodes are available, but multiplexing 
varied by run according to available samples and barcodes, with 
multiplexed MinION runs of three to 24 samples conducted. 
Sequencing libraries were prepared with a negative control (non-
template control from cDNA synthesis), which was sequenced as 
a barcoded sample. Sequencing was performed on a Dell Lati-
tude E5470 laptop (CPU: 6th Generation Intel Core i7-6820HQ 
[Quad Core, 2.7GHz, 8MB cache]; Memory: 16GB RAM; 
Storage: 1TB solid state drive) using MinKNOW (version avail-
able at the time, v1.7.3 to 18.12.9) with live basecalling turned 
off. The MinION functions as a “read-until” platform, whereby 
the length of sequencing runs is determined by the user when 
sufficient data has been produced (maximum 48h); therefore, 
this varied between runs. An offline version of MinKNOW 
provided by ONT was used due to varying internet quality 
at different locations. To ease the installation and use of bio-
informatic pipelines in the field, a lab-on-an-SSD approach 
was used to ensure a working bioinformatic environment was 
always available. The lab-on-an-SSD is a bootable USB3 drive 
containing a linux installation, ONT software and bioinfor-
matic analysis software, available from the ARTIC network 
resources, that offers a plug-and-play bioinformatic environ-
ment for most laptops. SSD image available as an open-source 
resource here: https://github.com/artic-network/fieldbioinformat-
ics/tree/master/lab-on-an-ssd),
Additional sequencing
Four samples shipped to the UK and extracted at APHA 
were sequenced using the metagenomic approach previously 
described (Brunker et al., 2015). Briefly, this involved host 
genomic DNA depletion of extracted total RNA using the on-
column DNase treatment in RNeasy plus mini kit (74134, 
Qiagen) followed by first- and second-strand cDNA synthe-
sis with a cDNA synthesis system kit (04379012001, Roche) 
and library preparation with a Nextera XT sample preparation 
kit (FC-131-1024, Illumina).
Cost estimates
The costs per sequenced sample were estimated for the 
MinION-based multiplex PCR approach and the previously used 
Illumina-based metagenomic approach (Brunker et al., 2015; 
Brunker et al., 2018). These estimates include processing from 
sample to sequence, i.e. incorporating all costs from the workflow 
shown in Figure 3 and any transportation costs associated 
with the shipment of samples to laboratory facilities. Rea-
gents and consumable costings assume a bulk buy for at least 
100 samples. For metagenomic sequencing, costs were based 
on previous quotes from UK sequencing facilities to process 
RABV samples, including sample shipment from Tanzania to the 
UK.
Bioinformatics and data management
i) Consensus sequence generation. Bioinformatic pipelines 
were run on the same laptop used for sequencing. A RABV 
version of the ARTIC network open-source bioinformatics 
pipeline (Quick et al., 2017) was used to generate consensus 
sequences for each barcoded sample (Figure 3B). Briefly, raw 
files were basecalled with the latest ONT software at the time 
(Albacore or Guppy) and demultiplexed with Porechop using 
stringent settings to select reads with barcodes at both ends of 
the read. Demultiplexed reads were then mapped with BWA 
(Li & Durbin, 2009) to a reference genome chosen according to 
the country of origin (Tanzania/Kenya: Genbank accession no. 
KF155002; Philippines: Genbank accession no. KX148260). 
Prior to variant calling, primer sequences were trimmed using 
their genome coordinates and their genome coverage normal-
ised. Variants were called using Nanopolish (Loman et al., 2015), 
which uses MinION signal-level data to “polish” the genome 
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assembly. Consensus sequences were generated under the condi-
tion that non-overlapping primer binding sites and sites for which 
coverage was <20X were masked by ambiguity code N. 
Illumina reads were processed according to a previously 
described method (Brunker et al., 2015). Briefly, Genome 
Analysis Toolkit (Poplin et al., 2017) was used to identify high 
quality SNPs using filters on strand bias (FS>60, SOR>4), 
mapping quality (MQ<40, MQRankSum≤12.5), read position 
(ReadPosRankSum≤8), and depth of coverage (DP<5). 
Consensus sequences were produced with a 75% majority base-
call rule. Raw and processed sequence data files were stored 
locally on the laptop’s internal hard drive or external SSDs. 
Data was transferred to University of Glasgow servers for 
storage and backup on return to the UK.
ii) Analysis/interpretation. Major and minor clade assignments 
were obtained for newly generated RABV sequences using 
Maximum Likelihood Clade Assignment (MLCA) as imple-
mented in RABV-GLUE (Singer et al., 2018). MCLA uses 
RAxML’s Evolutionary Placement Algorithm (Stamatakis, 2014) 
to select high-likelihood branch placements for a query virus 
sequence in a previously calculated phylogeny of virus reference 
strains. The reference phylogeny in RABV-GLUE was recon-
structed using maximum likelihood, and contains a representative 
set of RABV sequences obtained from recent studies of 
RABV diversity (Kuzmin et al., 2012; Troupin et al., 2016). 
Following MLCA, RABV-GLUE was used to import relevant 
sequences from GenBank to compare to the new sequence 
data from each area i.e. East Africa and the Philippines. 
GenBank sequences were curated from the same minor clade 
associated with each area according to MLCA and both 
GenBank and MinION sequences were filtered to include only 
sequences with >90% genome coverage. For sequences produced 
for this study that was 24 out of 34 sequences from East Africa 
and 44 out of 52 sequences from Philippines. Alignments were 
produced using MAFFT (Katoh & Standley, 2013) imple-
mented in RABV-GLUE. Maximum likelihood phylogenies 
were produced for each of the alignment sets using RAxML 
implemented in RABV-GLUE with a General Time Revers-
ible model of nucleotide substitution with the gamma model of 
Figure 3. Workflow from sample to sequence. A) Table of laboratory workflow steps with estimated timings and details of important reagents/
consumables; B) Bioinformatics workflow diagram; C) Estimated cost per sample for end-to-end rabies virus sequencing in-country using a 
PCR-based MinION approach versus the PCR-free metagenomic approach previously used in the UK. Costs assume a bulk buy of reagents 
for 100 reactions and a multiplex capacity of 24 samples per flowcell for MinION sequencing. 
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rate heterogeneity and a proportion of invariant sites and 1000 
bootstraps. Outgroups consisting of RABV genomes from other 
minor clades were included in tree building.
Training in MinION sequencing
Workshops were conducted in Kenya (11 participants) and the 
Philippines (10 participants) to provide hands-on training in 
MinION library preparation, sequencing and basic bioinfor-
matics. Participants typically had a background in molecular 
biology but most had never prepared sequencing libraries. 
RABV RNA from local archived samples was used for sequenc-
ing following the sample-to-sequence method described above. 
Basic bioinformatic training included an introduction to the 
command line and use of the lab-on-an-SSD resource with the 
RABV version of the pipeline. In addition to workshops, train-
ing of local researchers was conducted on a one-to-one or 
small group basis at every opportunity. Consent from partici-
pants was requested as part of a questionnaire to give feedback 
on training workshops. Only those that consented provided 
feedback (75% of participants). Given that no identifying or 
sensitive information was collected, no ethical approval was 
sought for this questionnaire.
Results
Validation of pipeline in UK laboratory
Amplicons from sample RV3227 sequenced on the NextSeq 
platform produced over 22million mapped reads and an 
average read depth of 6971 with >99% genome coverage. The 
same sample sequenced using the PCR-free metagenomic 
approach on the NextSeq produced 9498 mapped reads (0.4% 
of the total reads sequenced) with >99% genome coverage. 
Consensus sequences from each approach were identical. 
Amplicons from sample RAB16025 were sequenced on both 
NextSeq and MinION platforms, and metagenomic sequencing 
was also performed. Comparison between the three consensus 
sequences revealed 100% identity between Illumina consensus 
sequences (metagenomic vs PCR) and 99.98% identity between 
Illumina and MinION sequences. There were two SNPs between 
Illumina and MinION consensus sequences, highlighted in 
Figure 4.
Figure 4. Genome coverage profiles for a Tanzanian dog rabies virus sample sequenced by different methods. Blue: PCR amplicons 
(fragmented by Nextera library preparation) sequenced on Illumina NextSeq; orange: PCR amplicons sequenced on MinION sequencer; 
yellow: metagenomic sequencing on Illumina NextSeq. Asterisks indicate locations of single nucleotide polymorphisms between Illumina and 
MinION consensus sequences.
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In-country genome sequencing
RABV samples were sequenced across a range of settings 
in Kenya, Tanzania and the Philippines between 2017–2019 
(Table 1 and Figure 2). Using a lab-in-a-suitcase approach pro-
vided the flexibility to ensure that the necessary resources were 
available for sequencing in resource-limited settings but also 
in well-resourced laboratories if particular equipment was not 
available. In total, 84 brain tissue samples and one salivary 
gland sample were processed from sample to sequence in their 
respective country of origin. For all samples, a consensus was 
generated for all sites across the genome where coverage was 
≥20x (Brunker, 2019a). The majority of samples (~80%) 
achieved >90% genome coverage at a depth of at least 20x 
(Brunker, 2019b). Due to practical constraints, sequencing run 
times varied; therefore, the total throughput from each run 
was different. Instances where coverage dropped below 
20x may have been improved with longer sequencing times.
The total processing time from sample to sequence-ready library 
for a batch of 24 samples was ~15 hours (Figure 3A). Sequenc-
ing run length varied batch to batch and was determined by 
practical constraints and the expected output required for 100x 
read coverage for n samples in a run (and assuming loss of 
reads during demultiplexing). Typically, we found 5–8 hours 
was sufficient to get adequate coverage for multiplexed runs. 
For most samples, the time taken to process them end-to-end 
was 2–3 days when accounting for reasonable working hours 
(which are often restricted in laboratories) and processing a 
large number of samples (up to 24) for each run. The most time- 
consuming parts of the protocol were sample preparation for 
RNA extraction due to variation in the quality of brain tissue; 
PCR setup for a large number of samples (24 samples = 48 PCR 
reactions); and the normalisation of PCR products for sequenc-
ing libraries - samples with high concentrations of DNA often 
required an additional dilution step to provide suitable vol-
umes (>1µl) for pooling after normalisation (Figure 3). Work-
flow times can be reduced with multiple workers (estimated 
timings assume only one person is doing the work) and good 
preparation e.g. prior tube labelling/setup, the preparation of 
next steps during incubations, preparation of stock solu-
tions ahead of time etc, but careful work is required to follow 
workflow steps to avoid mistakes and introducing contamination.
Negative controls were included in each batch of samples proc-
essed and sequenced in most runs. Contamination was found 
in some batches, particularly during group training exercises 
(e.g. Philippines workshop batch), highlighting the importance 
of this quality control step. When contamination was detected 
during PCR quantification steps (concentration >1ng/µl), sam-
ple preparation was repeated from RNA extraction. However, 
some cross-contamination was not apparent until sequencing; 
therefore, a negative control should always be included in the 
sequencing library. A low level of cross-contamination was 
noted in all sequencing runs (a few hundred reads), often caused 
by amplicons with particularly high levels of amplification.
Costings
We estimated the full cost of sample-to-sequence prepara-
tion for RABV samples to give a better understanding of the 
costs involved to process field collected samples (Brunker, 
2019c). The cost reduced as improvements to the protocol and 
multiplexing capacity were made. Early runs, which had a low 
number of samples per flowcell and were used mainly for vali-
dation, were approximately £160 per sample. This reduced to 
~£60 per sample at full multiplexing capacity, i.e. 24 samples 
per flowcell (Figure 3C). Furthermore, the development of an 
effective washing procedure for flowcell reuse (“Nuclease-
flush”, Oxford Nanopore) means that, potentially, multiple runs 
per flowcell could be achieved. Therefore, we anticipate that 
this will reduce even further to ~£35 to £45 per sample (based 
on 2–6 reuses of one MinION flowcell). For example, a simi-
lar PCR-based sequencing approach for Zika virus in Brazil was 
able to yield ~150 samples per flowcell by making use of the 
nuclease-flush between runs (S. Hill, University of Oxford, per-
sonal communication). In comparison, sample shipment to the 
UK followed by sample-to-sequence costs for an Illumina- 
based metagenomic approach used previously for RABV 
WGS costs an estimated ~£205 per sample (Figure 3C). In 
terms of bioinformatic/data management costs, the SSDs used 
were typically purchased for £75–80 but are an optional com-
ponent of the workflow and therefore not included in the 
overall estimate.
Training
21 participants from veterinary and public health laborato-
ries across Tanzania, Kenya and the Philippines took part in 
four-day sequencing workshops held in-country. Each par-
ticipant prepared one sample during group laboratory sessions, 
providing hands-on experience of end-to-end preparation for 
MinION sequencing. Participants typically had experience in 
molecular laboratory methods such as PCR but most had never 
prepared sequencing libraries before. Feedback questionnaires 
revealed that participants were overall very satisfied with train-
ing workshops but indicated a desire for more comprehen-
sive bioinformatics training. At the end of each workshop, 
participants were asked to submit a mini research proposal and 
a commitment from their research institute to support MinION 
genomic work in order to obtain a MinION starter pack 
and additional reagents. In total, four MinION starter kits 
were provided to groups of researchers from the workshops 
to kick-start the application of their new training skills for 
genomics research. At the time of writing none of the groups 
had conducted sequencing mostly due to problems procuring 
additional reagents (either due to funding or supplier issues). 
However, we have offered ongoing support e.g. provision of 
extra reagents, linking up with local expertise to ensure projects 
can be completed and all are expected to sequence within the 
next few months.
Consensus sequence analysis
Major and minor clade assignments were obtained for all 
sequences using RABV-GLUE (see example in Figure 5), even 
for sequences with very poor consensus genome coverage of 
coding regions (as little as 15.1%; see underlying data; Brunker, 
2019b). Philippines sequences were all identified as Asian SEA4, 
a minor clade so far detected exclusively in the Philippines 
(Saito et al., 2013; Tohma et al., 2016, source: RABV-
GLUE). Subdivision within the Philippines subclade indicates 
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Figure 5. Example output from the online RABV-GLUE: an online tool for automated genotyping and interpretation of rabies virus 
(RABV) sequence data. A) Major and minor clade assignments for a Tanzanian RABV whole genome sequence (sample id=Rab16031, 
GenBank accession=MN726824); B) Phylogenetic placement of the sequence within the RABV-GLUE rabies virus reference phylogeny. This 
figure has been reproduced with permission from the University of Glasgow.
regional phylogeographic structure, as found previously (Saito 
et al., 2013; Tohma et al., 2016) but also further subdivi-
sion that may indicate structure at a finer spatial resolution 
(Figure 6). Tanzanian sequences were all from the Africa 1b 
lineage, as found previously (Brunker et al., 2015; Brunker 
et al., 2018). Interestingly, we detected two minor RABV 
subclades in Kenya; Africa 1a and Africa 1b (Figure 7). 
The limited RABV genetic data available for Kenya prior 
to our work (one WGS, nine complete/partial nucleoprotein 
sequences) are all Africa 1b subclade. 
Discussion
Through a series of sequencing applications and trainings con-
ducted in different settings between 2017–2019, we demon-
strate the feasibility of a cost-effective, in-country pipeline for 
WGS of RABV using the MinION. Although challenges exist, 
we show they are not insurmountable. Our pipeline offers both 
a scalable, low cost workflow that can be particularly benefi-
cial for sequencing a large set of archived samples and a rapid 
sample-to-sequence turnaround for priority samples to 
inform decision-making for disease management. We share 
our protocols and guidance to facilitate WGS of RABV, 
even in resource-limited settings, discuss its limitations and 
prospects for ongoing application.
Genomic data has become an important aspect of contempo-
rary infectious disease surveillance (Gardy & Loman, 2018). 
Yet for rabies and other neglected endemic diseases it is 
underused - largely limited to academic studies and retrospective 
analyses with more limited actionable outputs. Even well-
funded research projects can take up to six months from sample 
collection to dissemination of results (e.g. Brunker et al., 2018; 
Boykin et al., 2019), impeding the quick decision-making 
necessary for timely disease control. Using our MinION-based 
sequencing protocol, RABV samples can be sequenced in-
country in a matter of days and at a cost much lower than 
third-party sequencing facilities (Figure 3C), which typically 
requires the export of samples. We envision two broad applica-
tions of our protocols, for: 1) cost-effective batch sequencing of 
archived samples to characterize circulating RABV diversity, 
and 2) rapid in situ genomic surveillance of new cases, 
particularly during the endgame when such information can 
target appropriate responses. Many countries have repositories 
of archived tissue samples from rabid animals, which could be 
sequenced in bulk and therefore at low cost. These samples are 
potentially very valuable to characterise historical RABV diversity 
in a locality from which to compare to contemporary sequences. 
This comparison can show whether lineages continue to circulate 
or have disappeared, perhaps as a result of rabies control efforts. 
The latter option of rapid in-situ sequencing makes less use of 
cost-cutting measures such as multiplex sequencing, but the ben-
efit of genomic surveillance to gain time-critical insights into 
persisting or re-emerging RABV far outweigh the expense of 
re-emergence. Further options to reduce costs when sample 
numbers are low include combining runs with other pathogens 
or using ONT’s low-cost, lower throughput Flongle flowcells 
(e.g. Grädel et al., 2019).
To facilitate replicable sequencing in different settings, we 
provide detailed instructions for each stage of sample process-
ing. Each stage independently is relatively simple, requiring 
standard molecular techniques, such as PCR, or adherence to 
step-by-step protocols. However, as an end-to-end protocol, it 
is intensive and ideally undertaken by experienced laboratory 
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Figure 6. Maximum likelihood tree of rabies virus genomes from the Philippines. Genomes from the rabies virus Asian minor clade SEA4, 
which were sequenced in this study (n=44) and curated from GenBank (n=5). Colours indicate the administrative region associated with each 
sequence as shown on the map and internal node symbols indicate bootstrap support ≥80. Genbank sequences GU358653 and GU647092 
representing Asian minor clades SEA2a and SEA2b were used as an outgroup (branch not shown). Administrative shapefiles were obtained 
from https://www.diva-gis.org/datadown and plotted in R.
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Figure 7. Maximum likelihood tree of rabies virus genomes from Kenya and Tanzania. Genomes belonging to two minor clades in the 
rabies virus Cosmopolitan clade are highlighted, Africa 1a and Africa 1b, which were sequenced in this study (tip shapes, n=24) and curated 
from GenBank (n=220). The country of origin and number of sequences in each minor clade are annotated on a map of Africa and the 
location of Pemba sequences from a 2016/17 outbreak is annotated on the tree, indicating multiple introductions from the mainland. Genbank 
sequences representing other minor clades ME1a, ME1b and ME2 (KX148162, KX148190, KX148191) were used as an outgroup (branch not 
shown). Maps were generated with package rWorldMaps in R.
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workers. The workflow needs to accommodate constraints 
on working hours and fit with other workloads to enable 
routine implementation. Realistically, the estimated 15-hour 
workflow for sample-to-sequence (for a batch of 24 samples) 
should be conducted over a 2–3 day period, but could be per-
formed rapidly when required. Feedback from our training 
workshops indicated that hands-on training was valued and 
provided an appreciation of what it takes to produce qual-
ity sequence data. However, while useful as an introduction 
to MinION sequencing, workshops should be followed by 
extended one-on-one training and continued use to achieve full 
competency in performing the workflow.
Challenges
Sub-optimal storage due to frequent power cuts and lim-
ited local storage facilities are a challenge in LMICs. Previ-
ously we have encountered difficulties in WGS of RABV 
samples archived in laboratories under variable conditions for 
up to a decade due to RNA damage (Brunker et al., 2015). 
We found that the amplicon-based approach ensured not only 
efficient viral read throughput on the MinION but also that 
samples varying in quality could be sequenced in the same way 
and with the best chance of success (a worst-case scenario 
approach). Generating longer amplicons for RABV sequencing 
(Nadin-davis et al., 2017) has proven difficult for samples 
typical of these conditions (K. Brunker, unpublished report) but 
may be an option for in situ sequencing when samples are fresh. 
We were unable to perform quantitative reverse-transcription 
PCR (qRT-PCR) on samples during field trips due to lack of 
equipment, but if available, this could inform the sequencing 
approach and aid as a diagnostic tool (Marston et al., 2019). In 
addition, sequencing can usefully validate diagnostic results, 
e.g. a cat sample in the Philippines was determined positive by 
dRIT but shown to be negative during sequencing preparation 
(K. Brunker, unpublished report). Notes from the dRIT on this 
sample indicated it had been difficult to interpret, therefore the 
sequence information provided vital data to confirm the sample 
had been misdiagnosed as a false positive.
More generally, logistical challenges impact on infectious dis-
ease research in LMICs, from sample collection difficulties to 
limited internet and reliable electricity supplies and sourcing 
of reagents and consumables. A recent study found only 
two thirds of hospitals providing surgical care in 21 LMICs 
have a continuous electricity source or an available generator 
(Chawla et al., 2018), problems that only worsen in more 
remote areas. To overcome these issues, we used a lab-in-a-
suitcase approach, with portable equipment to enable quick 
setup in different locations using battery power if required. 
However, maintaining a cold chain was problematic. Access to 
generator backed -20°C (for reagents) and -80°C (RNA storage) 
freezers was limited, even in research facilities, and minor issues 
often taken for granted in UK labs (e.g. access to ice for bench-
work with reagents) were common. ONT have recently devel-
oped a field version of some of their sequencing kits, containing 
lyophilised reagents to mitigate cold chain constraints. Lyophilised 
reagents could be an option for future work but are expensive 
and would require significant bulk purchasing to be affordable. 
Moreover, few local suppliers can provide sequencing-specific 
reagents and a considerable mark-up is added to already 
monopolised prices in research-rich countries like the UK/USA. 
Ordering directly from the company comes with its own 
difficulties, including expensive shipment costs, import taxes 
and airway bills for the delivery of reagents under cold-chain 
conditions. Delays at customs can compromise reagent viabil-
ity and occurred frequently on our sequencing trips. To promote 
in-country scientists and genomic research, better solutions 
are needed for sustaining a reliable, affordable supply chain 
for reagents and consumables.
Bioinformatics and data management proved to be a bottleneck 
in our pipeline and are a primary target for optimisation. The 
lab-on-an-SSD method (ARTIC network) simplified the instal-
lation of bioinformatic software and available pipelines, but 
as this is a developing resource, we did encounter issues that 
stalled analysis. This was largely due to limited experience and 
lack of access to a dedicated bioinformatician to troubleshoot 
problems. In general there is a critical need for bioinformatics 
training in LMICs, which has been recognised as a priority area 
for development, e.g. the Pan African Bioinformatics Network 
for the Human Heredity and Health in Africa consortium and 
NIH-funded Application of Genomics and Modelling to the 
Control of Virus Pathogens (GeMVi). Future work will focus 
on support for bioinformatic pipeline development, including 
optimising barcoding assignment and consensus building 
thresholds for RABV samples. This may involve the integra-
tion of Read Assignment, Mapping, and Phylogenetic Analysis 
in Real Time (RAMPART), a promising new tool to assess 
genome coverage and reference matching for each barcode 
concurrently as sequencing proceeds. We sequenced com-
pletely offline to avoid problems with internet connection 
(normally necessary to initialise MinION sequencing) and limit 
reliance on data transfer to servers for data storage. Sequence 
data was stored locally on either internal or external hard drives, 
with subsequent transfer to university servers in the UK at a 
later date. However, data transfer was problematic with the 
large number of files produced (in one instance corrupting 
a hard drive) and using one laptop for all sequencing and 
subsequent analysis was slow. Identifying local or cloud-based 
data solutions is advised to ensure data backup and take 
advantage of high-performance computing resources when 
available, but will come at additional cost.
RNA extraction from brain tissue was time-consuming and 
typically yields a low viral proportion after depletion of host 
genomic DNA (Marston et al., 2013). It also remains one of 
the most costly aspects of the workflow at ~£6 per sample. 
Goharriz et al. (2017) have shown that complete viral genome 
sequence can be obtained from Whatman Flinders Technol-
ogy Associates (FTA) card samples without RNA extrac-
tion, which opens avenues for refining this part of the protocol 
and simplifying sample field collection and storage. Efforts to 
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sequence from FTA card samples in Tanzania have shown prom-
ise, producing partial genome data (K. Brunker, unpublished 
report), and may be an option in future for field surveillance.
There is potential for cross-sample contamination, particu-
larly when working with amplicon sequencing. This can occur 
both during library preparation and the bioinformatic stage of 
barcode demultiplexing following sequencing (Xu et al., 2018). 
As advised in Quick et al. (2016), we took precautions to mini-
mise amplicon contamination in pre-PCR areas, reagents and 
equipment, such as physical separation between pre- and post-
PCR areas, regular decontamination and aliquoting of reagents. We 
also processed and sequenced negative controls (in most runs) to 
assess the degree of contamination, finding a low level of 
amplicon contamination in most sequencing runs. However, the 
proportion of reads in the negative control relative to the total 
number of reads per run was low (median [range]=0.03 [0-1.5]%) 
for runs prepared outside of training workshops i.e. in normal 
working conditions. Contamination was most problematic 
in regions where products overamplified in certain samples, 
increasing the risk of cross-over to other samples. This could be 
mitigated by limiting the number of PCR cycles for high 
viral titre samples, if they can be assessed by qPCR prior to 
sequencing. Unsurprisingly, contamination was higher during 
training exercises (see underlying data; Brunker, 2019b) and any 
sequencing results from training should therefore be repeated 
for validation.
PCR bias may preferentially amplify specific haplotypes in a 
sample (Grubaugh et al., 2019). This has implications for the 
use of this type of data in intra-host diversity studies and our 
results indicate it can contribute to consensus sequence varia-
tion between platforms/approaches. Our comparisons between 
samples sequenced on different platforms (MinION vs Illumina) 
and with different methodology (PCR vs metagenomic) indi-
cate that intra single nucleotide variation (iSNV) can change 
the nucleotides that hold the majority frequency in RABV con-
sensus sequences. The extent to which this occurs may be influ-
enced by the frequency of primer mismatches, depth of coverage 
and initial viral input (Grubaugh et al., 2019). Minor consensus 
variation has no impact on our objective of using phylogenetic-
based methods to identify variants and spatio-temporal-genetic 
patterns. However, it does indicate that this sequencing 
approach will require some adjustment to accommodate 
in-depth analysis, such as inferring who-infected-whom and 
measuring intra-host diversity. Grubaught et al.’s experimen-
tal approach to “correct” such biases in amplicon-generated 
sequence data could be applied to limit false positive consen-
sus assignments and accurately estimate within-host diversity in 
future.
The main limitation of an amplicon-based approach is the 
requirement for prior knowledge of the pathogen for targeted 
sequencing. This can be an issue if little is known about circu-
lating RABV diversity in an area e.g. following an emergence 
event, an incursion of a new variant or where multiple 
divergent lineages co-circulate. We have found that primer 
design can accommodate a reasonable level of RABV diversity, 
but its application is still limited. Recent discoveries of novel 
lyssaviruses (Shipley et al., 2019), cross-species transmission 
events (Kuzmin et al., 2012; Mollentze et al., 2014a) and the 
emergence of new variants (Kotait et al., 2019) indicate that 
when an amplicon-based approach is insufficient, a less tar-
geted method would be useful to monitor threats as dog- 
mediated rabies is eliminated. Metagenomic sequencing is 
considered the gold standard for viral pathogen sequencing, 
offering an unbiased, untargeted approach but suffers from 
sensitivity issues when working with low viral titres. Success 
with RABV metagenomic sequencing varies according to sam-
ple quality and viral titre, with often <1% of reads mapping to a 
RABV reference sequence (Brunker et al., 2015). Therefore, 
a high sequencing throughput per sample is required. The 
MinION is not considered a high-throughput platform but recent 
and ongoing improvements to flowcell chemistry and data out-
put from the MinION (10–20Gb in 48hours) have advanced 
the feasibility of conducting whole genome viral metagenomic 
sequencing directly from clinical samples, even with low viral 
titre samples (Kafetzopoulou et al., 2018).
Opportunities
The value of genomic data cannot be understated and has yet 
to reach its full potential for RABV. While the emphasis of this 
paper is on the application of the workflow and not phylogenetic 
analysis, the genomic data has already provided new insights. 
For example, uncovering the presence of two RABV subclades in 
Kenya, including one that is closely related to the lineage found 
in Tanzania. The extent of cross-border transmission and the scale 
over which persisting RABV lineages circulate in East Africa 
will have important implications for national and regional control 
efforts. In Box 1, we suggest how genetic data can inform con-
trol measures at different stages in the pathway to elimination. 
In addition, during the application of our workflow in Tanzania 
we were able to show directly how genomic data enhanced 
an investigation of a rabies outbreak on the island of Pemba 
(K. Lushasi, Ifakara Health Institute, unpublished report). 
Pemba is a small island (988 km2) off the coast of Tanzania. 
After four years of sustained vaccination campaigns, rabies 
appeared to have been eliminated from Pemba, with the last 
case detected mid-2014. However, after a lapse in vaccination 
efforts there was a rabies outbreak in 2016–2017. Samples col-
lected in the early stages of the outbreak were exported to the 
UK as a priority for sequencing but still experienced a lag time 
of around three months. During our first field trip to validate in-
country MinION sequencing in Tanzania (2017), we had the 
opportunity to sequence more samples from the outbreak. Eight 
samples were sequenced with a turnaround of two days, yielding 
whole genome consensus sequences that provided evidence of 
multiple incursions from mainland Tanzania (see Figure 7). 
This emphasises the importance of maintaining vaccination 
coverage and continued surveillance on Pemba to contain 
incursions and sustain freedom from rabies.
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Box 1. Surveillance insights from genomic data
Here we highlight the current and prospective ways in which 
genetic data can be used to answer questions at different  
stages along the complex pathway towards elimination of rabies  
(Figure 8).
1. Characterize circulating variants and lineages:
a.    Identify host associations/biotypes to inform 
targeted vaccination, such as vampire bat versus 
dog rabies in Latin America (Kotait et al., 2019) or 
mongoose versus dog rabies in parts of Southern 
Africa (Nel et al., 2005), and the identification of 
domestic dogs as the reservoir host in a wildlife-rich 
ecosystem (Lembo et al., 2008)
b.    Assess lineage distributions in the context of 
political/administrative borders, such as provinces 
in the Philippines (Tohma et al., 2016), states 
in North Africa (Talbi et al., 2010) and East 
Africa (Brunker et al., 2015); and quantifying 
transboundary risks as shown by Trewby et al., 
2017.
c.    Determine the socio-ecological processes 
underlying local and long-distance transmission, for 
example the identification of long-distance human-
mediated movement of RABV lineages (Brunker 
et al., 2015; Denduangboripant et al., 2005; Trewby 
et al., 2017) or associations with human density 
and landscape accessibility (Dellicour et al., 2017; 
Dellicour et al., 2019).
2. Monitor progress of control:
a.    Report emergence and extinction of lineages as 
evidence of control failures or successes (Dudas 
et al., 2017)
b.    Integrate with data streams (e.g. case detection, 
bite patients, vaccination coverage) to resolve 
complexities in dynamics (Bourhy et al., 2016; 
Lembo et al., 2008; Viana et al., 2016)
c.    Identify epidemiologically connected areas that 
RABV lineages circulate between once control 
underway e.g. RABV spread associated with road 
networks, (Brunker et al., 2018; Talbi et al., 2010), 
spread between peri-urban and rural areas (Bourhy 
et al., 2016).
3. Enhance surveillance during endgame:
a.    Differentiate undetected endemic transmission 
versus incursions (Bourhy et al., 2016; Faria et al., 
2017; Zinsstag et al., 2017)
b.    Discriminate variants to verify freedom from 
dog rabies (Velasco-Villa et al., 2017) or identify 
emergence of new reservoirs, such as those seen 
in Latin America (primate/marmoset associated 
variants (Kotait et al., 2019), circulation in crab-
eating foxes (Carnieli et al., 2009), terrestrial 
carnivores associations in Mexico (Velasco-Villa  
et al., 2005))
c.    Exclude possibility that cases are due to vaccine 
reversion, given vaccine quality concerns in some 
settings (Suseno et al., 2019)
4. Post-elimination surveillance:
a.    Identify the origin of imported cases (animal or 
human) or new outbreaks to direct control and 
prevention efforts and limit spread (Mollentze et al., 
2013; Zhang et al., 2019)
WGS using portable nanopore technology is a rapidly mov-
ing field, with protocols and pipeline developments evolv-
ing quickly. Although this comes with the caveat that protocols 
have to evolve to keep up with changes, these developments 
bring cost savings and improve accuracy. New refinements 
are expected to reduce costs further from a current estimate 
of ~£60 to £35 per sample, according to projections with flow-
cell re-use or the smaller low cost Flongle flowcell. Moreover, 
ongoing optimisation to reduce reagent use (K. Brunker, unpub-
lished report) indicate that this can be reduced even further 
to the point where sample preparation/RNA extraction, rather 
than sequencing itself, become the most costly aspect of the 
protocol. Improvements to pore chemistry, kits and basecalling 
software have significantly improved the error rate, often con-
sidered the MInION’s Achilles heel. Single read accuracy has 
improved from 20% error rate of early phase 2014 releases to 
<5% error rate with R9.4.1 pore chemistry (Plesivkova et al., 
2019). The latest version shows further improvements with 
1D2 sequencing technology and error correcting algorithms 
reaching ~99.3-99.9% consensus accuracy (Wick et al., 2019). 
A major benefit of nanopore sequencing is the ability to convert 
raw data to basecalled sequence data in real-time. Although we 
did not have a GPU powered laptop to take advantage of this 
function, it offers an even speedier resolution for time-critical 
sample analysis to inform decision-making. ONT’s MinIT, 
a portable data processing unit, offers similar functionality but 
with the flexibility to use with different laptops.
Conclusions
Genomic research has the potential to leap-frog LMICs to 
the forefront of infectious diseases surveillance and control, 
and facing challenges head-on will hugely benefit the future 
of public and veterinary health. Most countries with endemic 
dog-mediated rabies currently have limited local sequencing 
capacity. These countries also suffer a heavy burden of other 
neglected endemic diseases, that could benefit from genomic 
research. The approach that we present is affordable and 
readily deployable to such settings with limited infrastructure, 
overcoming issues that typically constrain routine genomics 
surveillance, including cold chain, electricity and internet. 
Moreover, the approach is scalable and low-cost (~£60 per 
sample) for both sequencing large numbers of samples and for 
rapid turnaround to inform disease management. We predict 
further improvements to sequencing performance including 
cost-effectiveness, speed and accuracy, with further optimiza-
tion underway and protocols available to researchers (https://
github.com/kirstyn/rabies_minion; Brunker, 2019d; Brunker, 
2019e). Nonetheless, improvement to the supply and afford-
ability of reagents for LMICs’ scientists is an area that needs 
addressing, as is the development of bioinformatics resources 
and translation of genomic research findings to digestible 
recommendations for policy-makers. Overall, this in-country 
application can support capacity building and the sustainabil-
ity of routine genomic surveillance in LMICs, empowering local 
scientists to conduct cutting-edge research in their own 
backyard.
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Figure 8. Progress  towards elimination of dog  rabies and  role  for genomic surveillance. Detected animal rabies cases are shown 
in grey and human rabies cases in red, based on surveillance data from Ecuador (from SIRVERA). Data were used to inform hypothetical 
scenarios relevant to rabies circulation in Latin America to illustrate examples of how genomic surveillance can add value. Stages of genomic 
surveillance corresponding to Box 1 are shown with examples of inferences from genomic surveillance indicated by asterisks.
Data availability
Underlying data
Consensus sequences on Genbank, Accession numbers 
MN726802 - MN726882
Figshare: rabv_minionSeqConsensus.fasta. https://doi.org/ 
10.6084/m9.figshare.10282859.v1 (Brunker, 2019a)
Figshare: Table 1. Rabies virus samples sequenced on the 
MinION machine 2016–2019 in East Africa, Philippines and 
UK. https://doi.org/10.6084/m9.figshare.11111771.v1 (Brunker, 
2019b)
Figshare: Breakdown of costs to sequence rabies virus samples 
on MinION (spreadsheet). https://doi.org/10.6084/m9.figshare. 
11120405.v1 (Brunker, 2019c)
Extended data
Figshare: RabiesVirus_sampleToSequence_SOP. https://doi.org/ 
10.6084/m9.figshare.10742090.v1 (Brunker, 2019d)
Figshare: Rabies virus primer schemes. https://doi.org/10.6084/
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submit research proposals and commitment from their institutions to support MinION genomic
work in order to obtain MinION starter kits. They then state that four MinION starter kits were
provided to groups "to kickstart the application of their new training skills for genomic research". To
provide readers with a better idea of the impact of the training, it would be helpful to know how
many of the participants actually submitted proposals (with institutional commitment) as well as
how many "groups" received kits. Also, is there information on whether any of the proposed
projects have been initiated? 
 
Figure 5 - Although it is indicated in the table within Figure 5a and highlighted in the phylogeny in
Figure 5b, I would suggest including the name of the Tanzanian whole genome sequence in the
figure legend i.e. "...for a Tanzanian RABV whole genome sequence (tvla1_tz_Rab16031);"
 
Figure 6 - It would be useful to know the regions from which the Genbank sequences in the
phylogeny originated (do they overlap with any of those sampled in the study?). I would also like to
see a fully annotated tree (perhaps as extended data) that included bootstrap values, sequence
IDs and the regions and years associated with all the sequences.
 
Figure 7 - As for Figure 6 a fully annotated tree (as extended data) would be a helpful addition.
 
Figure 8 - It is unclear whether the data in this figure is hypothetical or real data from a specific
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Brunker   present an interesting paper describing an approach that can be used under minimalet al.
laboratory infrastructure and that could reduce the lag time from sample to sequence and epidemiological
action in LMICs. They propose an in-country pipeline for rapid whole genome sequencing (WGS) of
rabies viruses (RABV), one of the major neglected tropical disease causing a large public health and
economic burden in Asia and Africa. The approach is based on the MinION sequencing technology,
including a workflow from sample to sequence and the associated bioinformatics pipeline.
The paper is well written and documented. The authors provided a lot of information and incorporate
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 The paper is well written and documented. The authors provided a lot of information and incorporate
procedures for downstream analysis, interpretation, and management of genomic data in a surveillance
context. The feasibility of this methods was tested in different locations in Kenya, Tanzania and the
Philippines using the concept of a lab-in-a-suitcase platform:
To this aim, samples from Kenya (n = 10), Tanzania (n = 24) and the Philippines (n = 52) were sequenced
using three distinct technologies and 92 of them were sequenced in LMICs using the MinION sequencing
technology. The protocol included RNA extraction and PCR amplification of 400bp amplicons across the
entire genome (~11923bp), with an overlap of 50bp. Therefore, at least 30 different amplicons were
needed to cover the whole RABV genome. The costs per sequenced sample were estimated for the
MinION-based multiplex PCR approach and compared favorably with the previously used Illumina-based
metagenomic approach. Therefore, the authors claimed that they demonstrate the feasibility of real-time
sequencing of RABV to rapidly inform policy decisions and disease management. I would easily agree
that the first objective is reached and I really consider that as a great achievement which deserves
publication. But this does not seem to be fully the case for the second one (inform policy decision and
disease management). Most of the limitations of the techniques are presented in the discussion.
However, some of the limitations would require more discussion and others are simply not addressed at
all although some of these dramatically weaken the ability of this approach to accurately inform
epidemiological surveillance and complex epidemiological questions.
There are many studies published by other authors showing that samples collected in a defined
geographic area reflecting an endemic situation and during a limited period of time (a few months) differ
only by a very low number of SNPs. Any errors concerning the distribution of these SNPs along the
genomes and between the samples will have a dramatic effect on the phylogenetic tree reconstruction
and the derived inferences.
As mentioned by the authors, the MinION is so far not considered a high-throughput platform. One of the
major risks is the potential for cross-sample contamination, particularly when working with amplicon
sequencing. This was noticed by the authors “A low level of cross-contamination was noted in all
sequencing runs (a few hundred reads), often caused by amplicons with particularly high levels of
amplification”. This can occur both during library preparation and the bioinformatic stage of barcode
demultiplexing following sequencing as written by the authors but the major risk lies in the preparation of
the samples and their amplification. The authors stressed the fact that they took precautions to minimise
amplicon contamination in pre-PCR areas, reagents and equipment. However, all clinical biology
laboratories even in the developed countries have shifted to single tube amplifications to avoid these
contaminations. It appears unrealistic to think that such contaminations will not happen in a significant
percentage when performed in field conditions when many samples will be received and processed every
day and at least 30 different amplicons generated for each of them. This will unfortunately happen
independently of all authors’ efforts to train local people that are documented in this manuscript.  These
cross contaminations and mislabelling of tubes will have a strong effect on the final whole genome
sequences generated and consequently on some of the conclusions drawn from their phylogenetic
analysis.
I fully agree with the fact that improvements to pore chemistry, kits and basecalling software have
significantly improved the error rate of the MInION. However, despite these improvements every user will
agree that when used in the field condition the consensus accuracy reach only 98-99% which seems to
be quite low for many applications.
 
The authors are fair writing “Our comparisons between samples sequenced on different platforms
(MinION vs Illumina) and with different methodology (PCR vs metagenomic) indicate that intra single
nucleotide variation (iSNV) can change the nucleotides that hold the majority frequency in RABV
consensus sequences. The extent to which this occurs may be influenced by the frequency of primer
mismatches, depth of coverage and initial viral input”. This is further exemplified in Figure 4 where
locations of single nucleotide polymorphisms between Illumina and MinION consensus sequences are
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 locations of single nucleotide polymorphisms between Illumina and MinION consensus sequences are
shown (at least two on this example). However, I disagree with the rather superficial conclusion saying
“Minor consensus variation has no impact on our objective of using phylogenetic-based methods to
identify variants and spatio-temporal-genetic patterns”. This has to be demonstrated and is probably not
the case for many of the applications of genomic data on surveillance. I would bet that the longer internal
branches of the maximum likelihood tree linking the rabies virus genomes from Kenya and Tanzania to
those collected from Genbank sequences illustrate these points. Further the authors should comment on
the impact of the sites masked by ambiguity code N (coverage was <20X) and their final proportion on the
full genome sequences.
 
Two broad applications of the presented protocol are claimed by the authors such as characterization of
circulating RABV diversity, and rapid in situ genomic surveillance of new cases, particularly during the
endgame and I will agree that the error rate of the MinION will generally not interfere too much with such
applications. However later in the discussion they presented many more applications of genetic data to
inform surveillance (see Box 1, page 15: Current and prospective ways in which genetic data can be used
to answer questions at different stages along the complex pathway towards elimination of rabies). Among
the four main applications listed by the authors and their secondary objectives (10 are cited), at least 6 of
them (listed below) will not tolerate cross contamination, ambiguities in the sequencing, and sequencing
errors even in a very low percentage and therefore renders the proposed pipeline inapplicable for such
studies.
Identify host associations to inform targeted vaccination.
 
Assess lineage distribution in the context of political/administrative borders, quantifying
transboundary risks.
 
Determine the socio-ecological processes underlying local and long-distance transmission.
 
Resolve complexities in dynamics.
 
Identify epidemiologically connected areas that RABV lineages circulate between once control
underway.
 
Discriminate variants to verify freedom from dog rabies or identify emergence of new reservoirs.
 
This should be made very clear in the discussion even if we may all share the author’s hope that further
development in the technology will in the next years minimize the risk of sequencing errors.
 
In conclusion, the MinION based pipeline proposed is interesting to enhance surveillance during the
endgame and the post-elimination phases, stages that are not reached so far by many LIMCs, but is not
appropriate for addressing complex epidemiological questions related to RABV dynamics and drivers of
persistence and diffusion in an endemic or epidemic context.
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
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 Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Partly
 I have co-authored at least one paper with one of the authors of this paperCompeting Interests:
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Author Response 11 May 2020
, University of Glasgow, Glasgow, UKKirstyn Brunker
We are grateful for this positive review and critical insights to improve the manuscript. To address
the reviewers concerns we have emphasized the potential that we believe real-time sequencing
has to inform policy-decisions and management, whilst also highlighting the further work required
to put this into practice. As suggested, we now discuss limitations cautioned by the reviewer. In
response, we also provide examples of questions that WGS derived from our MinION protocol
would be sufficiently resolved and accurate to address. 
 
We agree that appropriate tube labelling is a concern but argue that this is so for all genomic
studies and not specific to our study. Furthermore, we emphasise that our approach is a multiplex
PCR, which involves closed tube amplification using combined pools of primers ( two tubes per
sample), not 30+ individual reactions, therefore minimising the risk of cross-contamination and risk
of mislabelling when working with many tubes. By including a negative control (processed from
cDNA stage) in sequencing runs we are able to monitor the level of cross-contamination and
identify high levels (based on read coverage across the sample set and how that compares to the
controls) that could impact results. While we did note some reads in negative controls the relative
proportion compared to the overall mapped reads in runs was low (median 0.03% of reads in the
negative, range 0-1.5%) for sequencing runs that were not part of training exercises.
Cross-contamination is a general concern for any type of sequencing and we do agree that it will
be increasingly hard to control in field situations. We now emphasize that in an endgame scenario,
where samples are increasingly valuable and informative and need to be processed rapidly in-situ
(i.e. in the field rather than a clinical biology laboratory), sequencing would likely be conducted
individually, i.e. one sample per flow cell. In such cases, cross-contamination would not be
expected and higher depth of coverage would address basecall ambiguity and mitigate concerns
(hopefully including tube labelling!). Nonetheless we appreciate the reviewers apprehension and
have therefore reduced our emphasis on how this approach can address complex epidemiological
questions. 
 
The error rate for nanopore sequences following consensus correction is around 0.3-0.7% (for the
sequencing chemistry versions we used), where quality scores are Q30. Although higher than
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 sequencing chemistry versions we used), where quality scores are Q30. Although higher than
Illumina (~0.1%) corrected nanopore sequences should be accurate enough for many uses aside
from perhaps within-host variation (although Nathan Grubaugh’s recent paper suggests that further
biases can be corrected to enable characterisation of within-host diversity even with amplicon
data). We have also further limited consensus miscalls by masking regions with low depth of
coverage. Multiple studies have now demonstrated the utility of nanopore sequences for viral
surveillance as noted by the references cited- ebola (Dudas et al), yellow fever (Hill et al), zika
)(Faria et al), dengue(Kafetzopoulou et al  etc and how these sequences can be used for
applications such as we have suggested in box 1. We disagree that the nanopore error rate will
impact sequences to the extent that they cannot discriminate different lineages or host-associated
variants, particularly at whole genome resolution, even with minor consensus errors. Comparisons
between Ilumina and nanopore generated sequences on the phylogenetic tree show that they
group tightly together and therefore the same conclusion would have been reached regardless of
platform. Furthermore, nanopore consensus sequencing accuracy continues to improve and has
now reached Q50 with R.10.3 flowcells.
 
More specifically, we agree that some questions, such as identification of host adaptation (e.g.
emergence in foxes from dogs in Turkey) and the mechanisms underpinning persistence in
etalternative hosts (see Nardus kudu/dogs/foxes) may require ultradeep sequencing (e.g. Marston 
al). These however are questions that we are struggling to resolve no matter what sequencing
approach is used, and are indicative of areas of biology for which we require more fundamental
understanding. Since MinION approaches will not be key to breakthroughs in these areas, we have
removed them from Box 1. Similarly, socio-ecological processes will be challenging to address, but
we argue that epidemiological and contextual data will be a greater limitation than genomic data. 
 
For those questions where we believe a MinION approach could be valuable, we have edited Box
1 to give examples:
For host associations, such as vampire bat versus dog rabies in Latin America or mongoose
(Kotait et al) vs dog rabies in parts of Southern Africa (Nel et al)
Lineage distributions in the context of political/ administrative borders, such as provinces in
the Philippines (Tohoma et al), states in North Africa (Talbi et al.) and East Africa (Tanzania
and Pemba mainland); and assessing transboundary risk as shown by e.g. Trewby et al)
Confirming epidemiologically connected areas is a clear question for areas in Latin America
now, e.g. Peru/ Bolivia and a logical and feasible extension from studies by Talbi et al.
(localities connected by road networks), Bourhy et al. (connectivity between peri-urban and
rural areas), Brunker at al. (connectivity between pastoralist areas)
Identification of long-distance human-mediated movement of lineages (Thailand paper, rural
to urban transmission, TZ examples).
We argue that resolving complexities in dynamics using genomic data integrated with
epidemiological data, such as distinguishing genetic lineages and their association with
spatio-temporal patterns, would be possible with nanopore consensus sequences e.g.
subtypes reported in Bourhy et al. (where divergence between subtypes was ~0.2-14%)
should be possible with MinION data even with minor consensus inaccuracies.
Discriminate variants to verify freedom from dog rabies or identify emergence of new
reservoirs, such as those seen in Latin America (Crab-eating fox, Carnieli et al,
primate/marmoset associated variants, Kotait et al). For example, Carnieli et al found a
divergence of ~9% in the G gene between RABV isolates from domestic v wild hosts,
variants which nanopore WGS are more than capable of discriminating.
Generally studies from other pathogens demonstrate this potential (previously mentioned above),
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Generally studies from other pathogens demonstrate this potential (previously mentioned above),
and although yet to be achieved for rabies, provide optimism for the future.  
  
 No competing interests were disclosed.Competing Interests:
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© 2020 Sabeta C. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.
 Claude Sabeta
OIE Rabies Reference Laboratory, Agricultural Research Council-Onderstepoort Veterinary Institute,
Onderstepoort, South Africa
The authors Brunker   have described and advocate a rapid in-country sequencing of whole viruset al.
genomes to inform rabies elimination programmes using Tanzania, Kenya and the Philippines as sites of
testing of this technology. Whereas genomic surveillance is not being used in Africa and Asia and as we
know this is due to limited infrastructure, costs, supply chains and other logistical challenges. This may
change as the global scientific community has adopted the zero human deaths by 30. This may result is a
shift in funding for this elimination programme as regional blocks may support this programme to be in line
with global goals for the elimination of rabies. With this surveillance approach, regional members will be
able to differentiate rabies variants from other wildlife, distinguish ongoing transmissions from incursions
as well as identifying sources of incursions. The authors described sequencing and bioinformatics
pipelines and validation process. Protocols for sample-to-sequence and a general purpose for analysis,
interpretation and management of rabies virus genome data are available making the approach described
here appealing to regional laboratories and members states. The concept of a portable, low-cost
sequencer (lab-in-a suitcase is interesting). Overall, the manuscript is well written and I have very few
issues that require clarification:
Para 4 - please explain what is meant by disease can circulate for extended periods at low levels in
the context of rabies.
 
In many of these countries, there are rabies virus repositories that date to many years back. What
would the authors such laboratories in terms of sequencing to inform rabies elimination
programmes?
 
The samples were collected by field officers, in actual fact a varied number, Kenya=10,
Tanzania=24 and the Philippines=52. Do these numbers in any way indicate how good the
different countries are in collecting and submitting samples? If so, how can this be improved so that
whole genome sequencing of viruses truly reflects the rabies situation in the countries?
 
On page 5, the authors indicated that samples were processed in settings with varying
infrastructure and resources - samples were confirmed using different methods from RIDT, to dRIT
and the FAT. Can the authors shed more light on the antibody preparation used in the dRIT and
also the FAT in the Philippines? What was the correlation between the results obtained by these
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also the FAT in the Philippines? What was the correlation between the results obtained by these
laboratories and the sequencing?
 
In the description of the Trizol method on page 5 - 50-100g should read 50-100mg.
 
Page 7 - please indicate the number of archived and tested samples to give the reader a sense of
the sample numbers.
 
On page 7, the authors indicated that extracted RNA was reverse transcribed first with the
Protoscript II kit and later Lunascript RT Supermix - was the rationale only to use reduced volumes
or they were other considerations?
 
I think the technology described in this manuscript is useful for the Asia and Africa, particularly as
the global community move towards rabies elimination human mediated dog rabies. Some of
the outputs have been taken up by Kenya, Tanzania and the Philippines. How do the authors
intend to disseminate such important technologies (particularly on minimising cross-contamination
in sequencing runs, preparation of sequencing libraries and bioinformatics training) for this purpose
to other regions of the two continents (if any)?
 
On page 10 - one salivary gland sample (amend).
 
Page 11 - Variations in quality of brain tissues was observed and generally influenced sample
preparation times - what would the authors advise on sample collection in general to overcome this
problem?
 
How do the authors plan to overcome the bottlenecks experienced with bioinformatics and data
management?
 
The authors indicated that prior knowledge about circulating RABV diversity in an area is important
- and we know many countries on the African and Asian continents do not have this knowledge.
How do the authors hope that member states on these continents can circumvent this issue?
 
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
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findings presented in the article?
Yes
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Epidemiology, virus evolution, virus diagnostics, method development and
validation.
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Author Response 11 May 2020
, University of Glasgow, Glasgow, UKKirstyn Brunker
We thank the reviewer for their positive remarks and in our revised manuscript we address each of
the minor issues as indicated below.
We now describe how endemic rabies circulates at low incidence and refer to examples
from Latin America where rabies control was largely achieved early this century, but
persistent foci have remained a challenge for elimination.
Archived tissue samples from rabid animals and publicly available sequences are potentially
very valuable. Archived samples could be sequenced in bulk and therefore at low cost.
Together with existing sequences they can characterize historical RABV diversity in a
locality from which to compare to contemporary sequences. This comparison can show
whether lineages continue to circulate or have disappeared, perhaps as a result of rabies
control efforts. We now explain this in the main text.
We have clarified that the number of sequenced samples in our study do not represent the
surveillance capacity of these countries. These samples were accessible through existing
collaborations and time allowed for their processing whilst optimizing our protocols and
delivering training workshops.
In the Philippines, dRIT antibody was prepared at RITM using plasmid antigen from National
Institute for Infectious Diseases, Tokyo Japan. Rabbit was used for hyperimmunization,
purify and biontinlylate (a paper has been submitted by RITM collaborators for publication of
this research). FAT antibody was commercial (Fujirebio). We were able to sequence virus
from all positively diagnosed samples (from all locations), aside from the one sample from a
cat in the Philippines (mentioned in the text) which was diagnosed positive by dRIT but
proved negative during preparation for sequencing (notes from the initial diagnosis had
indicated that this was a difficult to diagnose case and it was possibly negative).
We have corrected typographical errors (trizol units)
We tested n=11 archived samples but are unable to reference these in the methods as we
don’t have unedited gel images. However, details and annotated gel images can be found
here: https://doi.org/10.6084/m9.figshare.10282865.v1. In the text we refer only to
samples taken right through to sequencing stage (n=2) prior to field trips.
Extracted RNA first transcribed with Protoscript II kit and subsequently with Lunascript RT
supermix, because of the availability of this kit, its ease of application in the lab and its
reduced cost (we use reduced reaction volumes to allow 2.5x the normal recommended
reactions per kit).
We are very keen to disseminate the technology and protocols to as wide an audience as
possible- note a protocol has now also been added to protocols.io and is referenced in the
paper. We have therefore made our protocols openly available and will update them with
any improvements as they are discovered (see protocols.io etc etc). We also emphasize
caveats of the method (such as cross-contamination) and how they can be best avoided.
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caveats of the method (such as cross-contamination) and how they can be best avoided.
We are working broadly with laboratories in East Africa (G. Kour) and in the Philippines (C.
Bautista) as part of collaborative PhD studentships. We hope to conduct more training
workshops, including one later this year for participants from 3 East African countries and
funding permitting we will also conduct further training. For example we are currently
carrying out training in Peru and through the ARTIC network have been supporting training
in this technology elsewhere, including Brazil and several West African countries.
We have corrected typographical errors (salivary gland samples)
In general for sample collection, we advise collection of brainstem with homogenisation and
storage in RNA shield. This reagent has the advantage of both inactivating the sample and
protecting the RNA for future use. RNA later may aslso be used to preserve RNA but does
not fully inactivate the virus. Excellent protocols are available for this (CDC, Blueprint etc)
which we refer to. Importantly once collected, samples should be frozen as soon as possible
in a secure setting not subject to freeze-thaw cycles.
Our experience has been that training in bioinformatics is lagging in some LMICs, however
we are pleased to see several initiatives aiming to address capacity development in this
area. We are involved in the development and testing of publicly available support tools, like
lab-on-an-SSD, RAMPART and GLUE, for bioinformatics and data management, and we
are consolidating our workflow using Snakemake- a workflow management system to create
reproducible and scalable data analyses. This process and accompanying tools will make it
easier for laboratory scientists learning these methods and we now mention these in the
discussion.
 No competing interests were disclosed.Competing Interests:
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